A team of RIT faculty and students, led by Ph.D. student Evan Manfreda-Schulz, have published a paper featured on the cover of Optica Quantum.

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease. It causes multifocal central nervous system (CNS) inflammation that primarily affects the optic nerves and spinal cord ...

Chiasma, Inc. (NASDAQ:CHMA) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Chiasma, Inc., a commercial-stage biopharmaceutical ...

OSA rebrands as 'Optica' 20 Sep 2021 New name for The Optical Society references one of the organization's scientific journals. The Optical Society, previously known as the Optical Society of America ...

La fibra óptica nos permite navegar por internet a alta velocidad, pero también curar, diagnosticar e, incluso, predecir enfermedades.

Dublin-based biopharmaceutical group, Amryt, which specialises in the development of treatments for rare diseases, has completed the acquisition of the US business, Chiasma.

Amryt, the rare diseases company with Irish headquarters, expects to wrap up a near $340 million (€285 million) deal to buy US biopharma company Chiasma in the third quarter of the year. The ...

Publication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings DUBLIN, Ireland, and Boston MA, 28 June 2021 ...

Prompt and ongoing neuromyelitis optica treatments can help address symptoms and prevent future attacks, greatly improving a person's outlook.

CHIASMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chiasma, Inc. - CHMA ...

Commercial-stage biopharmaceutical company Chiasma Inc. (CHMA) announced Q1 results and has also agreed to merge with Amryt Pharma. After jumping 46% on the merger announcement yesterday, shares ...

Commercial-stage biopharmaceutical company Chiasma Inc. (CHMA) announced Q1 results and has also agreed to merge with Amryt Pharma. After jumping 46% on the merger announcement yesterday, shares ...